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Abstract
Major depressive disorder (MDD) and migraine are both more common among women than men. Women’s reproductive 
years are associated with increased susceptibility to recurrence of both conditions, suggesting a potential role of sex hormones 
in aetiology. We examined associations between comorbid migraine and clinical features of MDD in women, including 
relationships with lifetime reproductive events such as childbirth. Lifetime clinical characteristics and reproductive events 
in a well-characterised sample of 222 UK women with recurrent MDD, with (n = 98) and without (n = 124) migraine were 
compared. Women had all been recruited as part of a UK-based ongoing programme of research into the genetic and non-
genetic determinants of mood disorders. Multivariate analysis showed a specific association between the lifetime presence of 
migraine and postpartum depression (PPD) within 6 weeks of delivery (OR = 2.555; 95% CI: 1.037–6.295, p = 0.041). This 
association did not extend to a broader definition of PPD with onset up to 6 months postpartum. All other factors included 
in the analysis were not significantly associated with the presence of migraine: family history of depression, younger age 
at depression onset, history of suicide attempt and severe premenstrual syndrome symptoms. The finding that women with 
MDD and comorbid migraine may be particularly sensitive to hormonal changes early in the postpartum period leads to 
aetiological hypotheses and suggests this group may be useful for future studies attempting to characterise PPD and MDD 
phenotypes. The refinement of such phenotypes has implications for individualising risk and treatment and for future bio-
logical and genetic studies.
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Introduction
The lifetime prevalence rate of major depressive disorder 
(MDD) is estimated to be twice as high in women com-
pared to men (Kessler et al. 1993), with epidemiological 
studies showing increased risk of depressive episodes and 
symptoms in the reproductive phases of women’s lives, 
including the early postpartum period (O’Hara and Swain 
1996; Munk-Olsen et al. 2006) and during the menopausal 
transition (Freeman et al. 2006). MDD is highly comorbid 
with migraine (Breslau et al. 2003; Nguyen and Low 2013), 
and similarly, there is extensive literature demonstrating 
migraine is more prevalent among women compared to 
men (Vetvik and MacGregor 2017). The female to male 
ratio of migraine prevalence is not consistent across all age 
ranges and peaks during the reproductive years (Victor et al. 
2010; Buse et al. 2013). During women’s reproductive years, 
peaks in susceptibility to migraine occur during times of 
major hormonal changes. The menstrual cycle is linked with 
the onset of migraine and women are more susceptible to 
migraine attacks in the 4 day window surrounding the onset 
of menses (Granella et al. 2000; Vetvik et al. 2014). There is 
a reported improvement of migraine symptoms during preg-
nancy depending on the type of migraine (MacGregor 2007) 
followed by an increase in the postpartum period (Kvisvik 
et al. 2011).
MDD and migraine are both multifactorial conditions, 
shown to have a bidirectional relationship, in which each 
disorder increases relative risk for first onset of the other 
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(Breslau et al. 2000). The accepted view is that overlap-
ping underlying pathophysiology is likely to play a role in 
the association between the two conditions, for example, 
dysregulation of the serotonergic neurotransmitter system 
(Ressler and Nemeroff 2000; Deen et al. 2017). There is 
also evidence of shared genetic determinants (Yang et al. 
2018). The disproportionate prevalence of both conditions 
in women suggests sex hormones plausibly have a contrib-
uting role.
Migraine comorbidity in MDD has previously been found 
to be associated with more frequent and longer depressive 
episodes, and a higher severity of depressive symptoms 
(Oedegaard and Fasmer 2005; Hung et al. 2015). The find-
ings of a recent population-based study in Switzerland also 
suggest differential associations between the subtypes of 
MDD and the presence of migraine. Specifically melan-
cholic but not atypical MDD was found to be associated 
with the lifetime presence of migraine (Pisanu et al. 2020). 
However, there is a paucity of research examining the associ-
ation between comorbid migraine and MDD in women, and 
specifically relationships with lifetime reproductive events. 
Such research has the potential to increase understanding 
of the gender-specific associations between migraine and 
MDD and shine a light on the aetiology of these conditions.
The aim of the current study was to investigate the life-
time relationships between migraine and clinical features 
of MDD, including lifetime reproductive events, in a well-
characterised UK sample of women.
Methods
Data were collected as part of an ongoing programme of 
research into the genetic and non-genetic determinants of 
mood disorders including MDD. The research programme 
has UK National Health Service (NHS) Health Research 
Authority (HRA) approval–Research Ethics Committee 
(REC) reference (MREC/97/7/01) and local approvals in all 
participating NHS Trusts/Health Boards.
Recruitment of participants
Participants were recruited systematically via UK NHS psy-
chiatric services or non-systematically through the research 
team website, advertisements in local and national media 
and through patient support organisations.
The research programme inclusion criteria required par-
ticipants to be aged 18 years or over, able to provide written 
informed consent, meet DSM-IV criteria for major affec-
tive disorder and for mood symptoms to have started before 
the age of 65 years. Individuals were excluded if they: (i) 
experienced affective illness only as a result of alcohol or 
substance dependence or (ii) experienced affective illness 
only secondarily to medical illness or medication. All par-
ticipants were of UK White ethnicity due to a key focus 
of the research programme on genetic causes of affective 
disorders. Additional exclusion criteria for participants 
with MDD recruited into the research programme were (i) 
a first- or second-degree relative with a diagnosis of bipo-
lar affective disorder, schizophrenia, schizotypal disorder, 
delusional disorder, acute and transient psychotic disorders 
or schizoaffective disorder, and (ii) a history of experiencing 
mood incongruent psychosis or psychosis outside of mood 
episodes.
Participants included in the current study were unre-
lated women with a DSM-IV lifetime diagnosis of recur-
rent MDD, who were assessed for the presence of migraine 
(n = 288).
Psychiatric assessment
Participants were interviewed using the schedules for clini-
cal assessment in neuropsychiatry (SCAN) (Wing et al. 
1990), which provides detailed information about lifetime 
psychopathology. Where available, information was also 
gathered from review of psychiatric and general practice 
case-notes and combined with the interview data in order 
to establish a best-estimate lifetime diagnosis according to 
DSM-IV criteria. These data were also used to rate key life-
time demographic and clinical variables, for example, age of 
depression onset, number of depressive episodes, history of 
psychiatric admissions, family history of depression (defined 
as at least one first- or second-degree relative with a his-
tory of depression) and lifetime suicidal behaviour. Level of 
function during each participant’s lifetime worst episode of 
depression was assessed using the Global Assessment Scale 
(GAS) (Endicott et al. 1976). The GAS measures overall 
functioning during a specified time frame on a continuum 
from illness to health with scores ranging from 1 to 100 
(lowest-highest level of functioning). In cases where there 
was doubt, diagnostic and clinical ratings were made by at 
least two members of the research team blind to each other’s 
rating, and consensus was reached via discussion where nec-
essary. Inter-rater reliability was formally assessed using 20 
random cases. Mean kappa statistics were 0.85 for DSM-IV 
diagnosis and ranged between 0.81 and 0.99 for other key 
clinical categorical variables. Mean intra-class correlation 
coefficients were between 0.91 and 0.97 for key clinical con-
tinuous variables. Team members involved in the interview, 
rating and diagnostic procedures were all research psycholo-
gists or psychiatrists.
Lifetime reproductive events
At interview, parous women (n = 161) were asked about 
the lifetime occurrence of mood episodes in each perinatal 
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period (during pregnancy up to 6 months postpartum). A 
rating was made of the lifetime most impairing episode of 
perinatal depression categorised as one of: (i) no perinatal 
depressive episodes; (ii) depressive episode with onset dur-
ing pregnancy; (iii) postpartum depression (PPD) with onset 
up to 6 months following delivery. A narrow onset criterion 
for PPD restricted to the first 6 weeks following delivery was 
also rated to be consistent with both DSM-5 and ICD-11 
definitions of the postpartum period.
As part of a wider set of questionnaires completed and 
returned after the interview (response rate 85%), women 
were asked a series of questions about age at menarche, 
menstrual cycle regularity and premenstrual symptoms. 
Four items were used to assess the psychological aspects 
of premenstrual syndrome (PMS): Just before the start of 
your period, do/did you usually: (i) have less energy than 
usual or get tired more easily? (ii) feel more sad, blue or 
depressed? (iii) feel more irritable or get upset more eas-
ily? (iv) have any other changes in health or mood? Four 
possible responses to these items were: ‘No’, ‘A Little’, 
‘Some’ and ‘A lot’ (rated 0–3) which for the purpose of 
analyses were dichotomised into ‘No’ or ‘A Little’ (rated 0) 
vs. ‘Some’ or ‘A lot’ (rated 1). These four items were also 
summed to form a short premenstrual symptom scale with 
scores ranging from 0 to 12.
Migraine assessment 
The lifetime presence of migraine was assessed using a 
self-report bespoke questionnaire, completed at the end of 
the interview and returned directly to the interviewer. The 
questionnaire consisted of 10 items relating to migraine fre-
quency, character, duration, severity, associated symptoms 
and aggravating and relieving factors. Participant responses 
were used to make a lifetime diagnosis of migraine accord-
ing to criteria adapted from the International Headache Soci-
ety diagnostic criteria second edition (International Head-
ache Society 2004). Women were stratified into those with 
a lifetime history of migraine (MDD + m) (n = 98, n = 69 
parous) and those without a history of any headaches or 
migraine (MDD − m) (n = 124, n = 92 parous). Those with 
a history of tension headaches or headaches not reaching 
migraine criteria were excluded from the analysis (n = 66).
Analysis
As the majority of data were not normally distributed, non-
parametric statistical tests were used. For comparisons of 
demographic and clinical features between the MDD + m 
and MDD − m groups, chi-squared tests and Mann–Whitney 
U tests were used to compare categorical and continuous 
variables, respectively. To identify which lifetime clinical 
features best predicted the presence of migraine in MDD, 
all lifetime clinical variables significant at the 5% level 
(p < 0.05) were included as explanatory variables in a binary 
logistic regression model (enter method), with MDD + m vs. 
MDD − m as the outcome variable. All demographic vari-
ables found to be significant at p < 0.05 were also included 
as explanatory variables. We also included age at interview 
in the model as a potential confounder. Statistical analyses 
were carried out using the Statistical Package for the Social 
Sciences (SPSS) version 27.0.
Results
Demographic characteristics
There were no significant associations between the presence 
of migraine in the women with MDD and the demographic 
characteristics examined (Table 1).
Clinical features
Women with MDD + m had a significantly younger median 
age of depression onset, defined as the age at first impair-
ment due to depression (23 vs. 27 years, p = 0.006), and were 
more likely to have a family history of depression (94.1% 
Table 1  Demographic characteristics of women with MDD with and without migraine
MDD + m, major depressive disorder with migraine; MDD − m, major depressive disorder without migraine; IQR, inter-quartile range. Numbers 
vary for each variable due to missing data
MDD + m (n = 98) MDD − m (n = 124) p-value
Age at interview, years, median (IQR) 48 (17) (n = 98) 52 (19) (n = 124) 0.084
Systematically recruited, % (n) 40.8 (40/98) 53.7 (66/123) 0.058
Highest occupational level (professional), % (n) 55.9 (52/93) 56.9 (66/116) 0.887
Highest educational level (higher education), % (n) 27.5 (25/91) 25.2 (28/111) 0.718
Marital history (has married), % (n) 78.6 (77/98) 85.5 (106/124) 0.179
Ever regular tobacco smoker, % (n) 54.8 (51/93) 43.3 (52/120) 0.096
Heaviest weekly alcohol consumption, units, median (IQR) 11 (30) (n = 88) 10 (18) (n = 121) 0.104
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vs. 80.6%, p = 0.007) and to have attempted suicide (41.2% 
vs. 22.0%, p = 0.002) than women with MDD − m (Table 2). 
The two groups were however not significantly different in 
terms of lifetime number of depressive episodes per illness 
year, history of psychiatric admission, lifetime presence of 
psychotic symptoms and severity of functional impairment 
during the worst episode of depression as measured accord-
ing to the GAS.
Lifetime reproductive events
Parous women with MDD + m in the sample were signifi-
cantly more likely to have experienced a lifetime episode 
of PPD within 6 weeks of delivery compared to parous 
women with MDD − m (44.9% vs. 27.2%, p = 0.019). This 
association did not extend to a broader definition of a life-
time episode of PPD within 6 months of delivery, or to an 
even broader definition of any lifetime perinatal depressive 
episode (defined as any lifetime depressive episode with 
onset either during pregnancy or up to 6 months postpar-
tum). Women with and without migraine did not differ 
significantly in terms of the proportion who experienced 
their first episode of depression within 6 months postpar-
tum (23.2% vs. 23.9%), age at menarche (13 years in both 
groups) or history of a regular menstrual cycle (76.2% vs. 
78.2%, respectively). For one of the four PMS symptoms 
‘other changes in health or mood’, a significantly higher 
proportion of women with MDD + m reported the symp-
tom as occurring ‘some’ or ‘a lot’ compared to women 
with MDD − m (63.0% vs. 46.7%, p = 0.033). The other 
three PMS symptoms showed the same trend but were not 
significant. The median overall total PMS score was higher 
in the MDD + m group (9 vs. 8), just reaching statistical 
significance (p = 0.041).
The following demographic and lifetime clinical char-
acteristics were included as explanatory variables in the 
multivariate analysis: age at depression onset, family his-
tory of depression, history of suicide attempt, lifetime PPD 
within 6 weeks of delivery and total PMS score. The single 
factor found to be significantly associated with the pres-
ence of migraine in women with MDD was PPD within 
6 weeks of delivery (OR = 2.555; 95% CI: 1.037–6.295, 
p = 0.041). This explained 23.5% (Nagelkerke R2 = 0.235) 
of the variance.
Table 2  Lifetime clinical characteristics and reproductive events of women with MDD with and without migraine
MDD + m, major depressive disorder with migraine; MDD − m, major depressive disorder without migraine; PPD, postpartum depression; IQR, 
inter-quartile range; GAS, Global Assessment Scale; PMS, premenstrual syndrome. Significant results at p < 0.05 are shown in bold. Numbers 
vary for each variable due to missing data (perinatal episodes reported for parous women only)
a Family history of depression: defined as at least one first- or second-degree relative with depression
MDD + m (n = 98) MDD − m (n = 124) p-value
Age of depression onset, years, median (IQR) 23 (10) (n = 98) 27 (15) (n = 123) 0.006
No. depressive episodes per illness year, median (IQR) 0.2 (0.2) (n = 97) 0.2 (0.3) (n = 123) 0.695
History of suicide attempt, % (n) 41.2 (40/97) 22.0 (27/123) 0.002
History of psychiatric admission, % (n) 43.5 (37/85) 43.6 (44/101) 0.996
History of psychosis, % (n) 12.2 (12/98) 13.1 (16/122) 0.847
Family history of  depressiona, % (n) 94.1 (80/85) 80.6 (79/98) 0.007
GAS lifetime worst in depressive episode, median (IQR) 35.5 (8) (n = 98) 35 (8) (n = 124) 0.470
Lifetime reproductive events
   Lifetime any perinatal depressive episode, % (n) (vs. no perinatal depressive episode) 58.0 (40/69) 54.3 (50/92) 0.647
   Lifetime PPD within 6 months of delivery, % (n) (vs. no perinatal depressive episode or 
depressive episode in pregnancy)
50.7 (35/69) 42.4 (39/92) 0.294
   Lifetime PPD within 6 weeks of delivery, % (n) (vs. no perinatal depressive episode, 
depressive episode in pregnancy or PPD later than 6 weeks postpartum)
44.9 (31/69) 27.2 (25/92) 0.019
   First depressive episode within 6 months postpartum, % (n) 23.2 (16/69) 23.9 (22/92) 0.915
   Age at menarche, years, median (IQR) 13 (3) (n = 89) 13 (2) (n = 101) 0.501
   Lifetime regular menstrual cycle, % (n) 76.2 (64/84) 78.2 (79/101) 0.743
   PMS have less energy than usual or get tired more easily—some or a lot, % (n) (vs. no or 
a little)
67.9 (55/81) 60.4 (58/96) 0.302
   PMS feel more sad, blue or depressed—some or a lot, % (n) (vs. no or a little) 68.6 (59/86) 63.4 (59/93) 0.466
   PMS feel more irritable or get upset more easily—some or a lot, % (n) (vs. no or a little) 81.2 (69/85) 68.7 (68/99) 0.053
   PMS have any other changes in health or mood—some or a lot, % (n) (vs. no or a little) 63.0 (51/81) 46.7 (43/92) 0.033
   Total PMS score (range 0–12), median (IQR) 9 (5) (n = 81) 8 (7) (n = 92) 0.041
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Discussion
This is the first study to date to investigate differences in 
a range of both clinical characteristics and lifetime repro-
ductive events between women who have MDD with and 
without comorbid migraine. The presence of comorbid 
migraine was significantly associated with lifetime history 
of PPD within 6 weeks of delivery, even after controlling 
for other significant demographic and clinical differences 
between the groups in multivariate analysis.
Our findings suggesting an association between 
migraine and PPD overlap with those of a recent large 
Swedish population-based study to identify character-
istics and predisposing factors associated with different 
perinatal depression trajectories (pregnancy depression, 
early postpartum onset, late postpartum onset and chronic 
depression) (Wikman et al. 2020). Migraine was one of the 
characteristics associated with all perinatal depression tra-
jectories when compared with women defined as healthy 
(no depressive symptoms during pregnancy or postpartum 
and no history of depression). The results differ in that our 
findings suggest a specific association between migraine 
and depression with an early postpartum onset (within 
6 weeks after delivery). The more broadly defined occur-
rences of PPD within 6 months of delivery and any peri-
natal depressive episode were not significantly associated 
with the presence of migraine in our sample. However, 
there are a number of methodological differences between 
the studies, including that our study focused specifically 
on women with MDD.
A small number of previous cohort studies, also not spe-
cifically examining women with MDD, have shown women 
with migraine to be at high risk for perinatal mental illness. 
Cripe et al. (2010) examined the relationship between his-
tory of migraine and depressive symptoms in pregnancy in 
a large cohort of Peruvian women (n = 2293) who were all 
interviewed within 4 days of delivery during their postpar-
tum stay in hospital. The adjusted odds of moderate to severe 
depressive symptoms during pregnancy among women with 
a history of migraine (55.1%) were 2.06 times that of women 
without a history of migraine (36.7%). Similarly among a 
cohort of 1321 women interviewed during the first trimes-
ter of pregnancy in the United States, those with a history 
of migraine had an increased odds of moderate to severe 
depressive symptoms during pregnancy compared to those 
without a history of migraine (16.4% vs. 12.7%; OR: 1.60) 
(Orta et al. 2015). A prospective cohort study of 1423 preg-
nant women examining a wide range of potential risk fac-
tors for PPD including pre-pregnancy medical illness found 
women with PPD in comparison with women without PPD 
reported higher rates of pre-pregnancy migraines in univari-
ate, but not multivariate, analyses (Katon et al. 2014).
Our finding of an association between history of migraine 
and PPD among women with MDD is likely to be due to a 
complex interaction of psychosocial and biological factors. 
Psychosocial factors might include, for example, the diffi-
culties of living with migraine symptoms in the postpartum 
period increasing risk of depression. Potential neurobiologi-
cal factors include overlapping mechanisms implicated in 
the pathophysiology of both migraine and PPD, including 
the hypothalamic–pituitary–adrenal (HPA) axis (Peres et al. 
2001; Glynn et al. 2013), immune system (Bruno et al. 2007; 
Anderson and Maes 2013), neurotransmitter circuits (Hamel 
2007; Moses-Kolko et al. 2008) and most obviously sex hor-
mones. As highlighted in a recent review, fluctuations in hor-
mone concentrations, in particular oestrogen, are thought to 
account for the higher prevalence ratio of migraine in women 
during the reproductive years (Vetvik and MacGregor 2017). 
Specifically, women with migraine have been found to have 
a faster rate of oestrogen decline in the late luteal phase of 
the menstrual cycle compared to healthy controls (Pavlović 
et al. 2016). Similarly, a hallmark of the postpartum period 
is the drop in oestrogen immediately after childbirth. Early 
work in this area found evidence that women with a his-
tory of PPD may be differentially sensitive to these rapid 
hormonal changes by demonstrating that the add-back and 
subsequent withdrawal of reproductive hormones increased 
depression scores only in women with a prior history of 
PPD (Bloch et al. 2000). Depressive symptoms peaked in 
intensity during the withdrawal phase in this sample. More 
recently, a genome-wide association study found that women 
with PPD had an increased sensitivity to oestrogen signal-
ling, with significant gene expression changes in oestrogen-
responsive genes (Mehta et al. 2014). Oestrogen-mediated 
epigenetic changes have also been found to be associated 
with PPD (Guintivano et al. 2014). In light of these findings, 
the existence of a hormone-sensitive PPD phenotype has 
been proposed (Schiller et al. 2015).
The association between history of migraine and PPD 
in our sample did not appear to be explained by women 
in the migraine group experiencing more severe or more 
frequent mood episodes over the course of their lives. 
A number of lifetime clinical characteristics, including 
number of episodes per illness year and level of function-
ing during the worst episode of depression, did not dif-
fer significantly between the migraine and no migraine 
groups. Furthermore, the association remained significant 
in multivariate analysis which controlled for earlier age of 
onset of depression and history of suicide attempts, both of 
which were significantly associated with the presence of 
migraine in univariate analysis. Our findings suggest this 
group of women with MDD and comorbid migraine may 
be particularly sensitive to hormonal changes early in the 
postpartum. Despite there being no difference in the age at 
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menarche or proportion of women reporting regular men-
strual cycles between the groups, women with a history of 
migraine did have a significantly higher overall PMS score 
but this did not remain significant in multivariate analysis. 
In our univariate analyses, women in the migraine group 
were also significantly more likely to report other changes 
in health or mood premenstrually, although we were una-
ble to elicit whether or not this included migraine. For this 
reason and multicollinearity with total PMS score, we did 
not include this variable in the multivariate analysis.
Findings from the international perinatal psychiatry con-
sortium (Postpartum Depression: Action Towards Causes 
and Treatment (PACT) Consortium 2015) have suggested 
PPD to have several broadly defined distinct phenotypes dif-
ferentiated by the timing and severity of symptoms, compli-
cations in the perinatal period and history of mood disorders. 
The authors specifically suggest that the timing of symptom 
onset might be a useful indicator for use in future biological 
and genetic studies; as to date, the heterogeneity of PPD has 
made identification of common genes or common biomark-
ers difficult. Our findings are consistent with these findings 
and the proposed existence of a hormone-sensitive PPD 
phenotype (Schiller et al. 2015) suggesting that history of 
migraine in women with MDD may represent a group who 
are particularly sensitive to hormonal changes early in the 
postpartum.
The women in our study were recruited as part of a large 
on-going genetic epidemiology study of mood disorders; 
therefore, the sample is limited to individuals of UK White 
ethnicity and is likely to not be fully representative of the 
broader clinical population of women with MDD. Neverthe-
less, the strengths of this study lie in its nationwide recruit-
ment of participants and well-characterised sample. A fur-
ther potential limitation of this study is that the presence/
absence of migraine was determined by self-report. The 
questionnaire has however previously been shown to have 
excellent specificity and modest sensitivity by comparing 
the headache diagnosis derived from the questionnaire with 
the clinical diagnosis of a consultant neurologist (Samaan 
et al. 2009). Due to sample size limitations, we were unable 
to stratify the migraine group further by the presence of 
aura or headache intensity or frequency specifically in rela-
tion to the menstrual cycle. We were also unable to examine 
temporal relationships between the occurrence of migraine 
and mood symptoms and episodes and the potential role of 
psychopharmacological treatments due to the cross-sectional 
design. Our results require replication, ideally in prospec-
tive studies with larger sample sizes which would also allow 
for the collection of data on current medication being used 
for the treatment of both migraine and MDD. Such studies 
would help address the clinical utility of migraine comor-
bidity in individualising risk of PPD in women with major 
depression.
Conclusions
We have found a specific association between migraine 
and PPD within 6 weeks postpartum in parous women with 
recurrent MDD. This finding suggests women with MDD 
and comorbid migraine represent a group who are particu-
larly sensitive to hormonal changes early in the postpartum. 
This group may be useful for future studies attempting to 
characterise PPD and MDD phenotypes. The refinement of 
such phenotypes has implications for advances in individu-
alising treatment and future biological and genetics studies.
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